Oral OAB drugs used in 30% of NMIBC patients on intravesical therapy; neuromodulation almost never used
Retrospective · Urology · 2026-10-10. Number 5 in the UrologyWatch Top 5 for October 10, 2026.
In a retrospective claims analysis of 2,978 NMIBC patients receiving intravesical BCG or chemotherapy, 29.6% received LUTS therapy, mostly alpha blockers (19.9%) and anticholinergics (13.7%). Beta-3 agonists were used in 1.3%, botulinum toxin in 0.3%, and no patients received sacral neuromodulation or PTNS.
Why it matters: This retrospective study shows minimally invasive OAB options are essentially unused in NMIBC patients on intravesical therapy, highlighting a potential gap in symptom management, though the association with worse…
Source: Urology · PubMed 42854855 · DOI 10.1016/j.urology.2026.10.005
Loading today's edition…